| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01980316 | CVD | Drug: Argatroban|Drug: non-argatroban treated group | Xinfeng Liu|Jinling Hospital, China | Phase 4 | 2010-04-01 | 2015-10-21 |
| NCT00268762 | Ischemic Stroke | Drug: argatroban | The University of Texas Health Science Center, Houston | Phase 1|Phase 2 | 2003-02-01 | 2014-11-03 |
| NCT02448069 | Stroke|Cerebral Ischemia | Drug: Argatroban | The University of Texas Health Science Center, Houston | Phase 2 | 2015-05-01 | 2015-05-28 |
| NCT01734252 | Achievement of a Sufficient Thrombosis Prohpylaxis in Clitically Ill Patients With Heparin Resistance | Drug: Argatroban | Medical University Innsbruck | Phase 2 | 2012-06-01 | 2015-04-16 |
| NCT00861692 | Heparin-induced Thrombocytopenia Type II | Drug: argatroban | Mitsubishi Tanabe Pharma Corporation | Phase 2 | 2009-04-01 | 2016-07-01 |
| NCT01163604 | CVD | Drug: Argatroban|Drug: non-argatroban treated group | Jinling Hospital, China | Phase 4 | 2010-08-01 | 2015-10-21 |
| NCT01246011 | Coronary Artery Bypass Graft Surgery|Presence of Heparin/Platelet Factor 4 Antibody | Drug: Argatroban and warfarin | Massachusetts General Hospital|GlaxoSmithKline | Phase 4 | 2010-11-01 | 2012-03-09 |
| NCT00798525 | Heparin Induced Thrombocytopenia (HIT) | Drug: Argatroban|Drug: Lepirudin | Heinrich-Heine University, Duesseldorf | Phase 4 | 2009-01-01 | 2012-06-20 |
| NCT00787332 | Suspected Heparin-Induced Thrombocytopenia | Drug: Desirudin or Argatroban庐 | Canyon Pharmaceuticals, Inc. | Phase 4 | 2008-09-01 | 2013-01-06 |
| NCT01464788 | Ischemic Stroke | Drug: Argatroban|Drug: Argatroban | Andrew D. Barreto, MD|The University of Texas Health Science Center, Houston | Phase 2 | 2011-10-01 | 2015-05-11 |
| NCT00198588 | Heparin-Induced Thrombocytopenia | Drug: argatroban | Ministry of Health, Labour and Welfare, Japan|Mitsubishi Tanabe Pharma Corporation | Phase 3 | 2005-06-01 | 2008-11-11 |
| NCT00035178 | Kidney Failure, Chronic|Renal Disease, End-Stage | Drug: Argatroban | Texas Biotechnology Corporation|Encysive Pharmaceuticals | Phase 4 | 2002-05-01 | 2005-06-23 |
| NCT00039858 | Thrombocytopenia|Thrombosis | Drug: Argatroban | Encysive Pharmaceuticals|GlaxoSmithKline | Phase 4 | 2003-09-01 | 2007-01-10 |
| NCT00508924 | Coronary Artery Disease|Angina, Unstable | Drug: Argatroban|Drug: Argatroban|Drug: Argatroban|Drug: Heparin | Mitsubishi Tanabe Pharma Corporation | Phase 2 | 2005-08-01 | 2012-11-06 |
| NCT00153946 | Stroke | Drug: Edaravone | Combination Therapy for Acute Ischemic Stroke Study Group|Japan Cardiovascular Research Foundation | Phase 4 | 2004-08-01 | 2008-05-12 |
| NCT01304238 | Acute HIT II (Heparin-induced Thrombocytopenia Type II) | Drug: lepirudin|Drug: danaparoid|Drug: argatroban|Drug: fondaparinux | GlaxoSmithKline | | 2009-02-01 | 2011-03-10 |
| NCT02935530 | Gynecologic Neoplasms|Venous Thromboembolism|Low Molecular Weight Heparin|Argatroban | Drug: s-LMWH|Drug: LMWH|Drug: Argatroban | Huazhong University of Science and Technology | Phase 3 | 2016-01-01 | 2016-10-14 |
| NCT01162824 | Endothelial Dysfunction|Atherosclerosis|Inflammation|Myocardial Ischemia | Drug: Acetylcholine|Drug: Adenosine | St George's Healthcare NHS Trust | | 2011-01-01 | 2011-02-22 |
| NCT00921856 | Coronary Vasospasm|Microvascular Angina|Coronary Artery Disease | Other: Intracoronary acetylcholine provocation test | Peter Ong, MD|Robert Bosch Medical Center | | 2007-11-01 | 2015-11-02 |
| NCT01911624 | Staphylococcus Aureus Bacteraemia | Drug: direct thrombin inhibition|Drug: enoxaparin | Universitaire Ziekenhuizen Leuven | Phase 2 | 2013-01-01 | 2016-07-11 |
| NCT00603824 | Heparin-Induced Thrombocytopenia | Drug: fondaparinux|Drug: argatroban or lepirudin | Methodist Healthcare|University of Tennessee | Phase 4 | 2008-01-01 | 2016-09-12 |
